Immunosuppression News and Research

RSS
Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Live malaria parasites in the skin shut down immune responses and block vaccine function: Study

Live malaria parasites in the skin shut down immune responses and block vaccine function: Study

Athersys presents data supporting MultiStem programs

Athersys presents data supporting MultiStem programs

Steroids can raise cardiovascular risks in post-transplant patients

Steroids can raise cardiovascular risks in post-transplant patients

Novel combined immunotherapy promising for treatment of malignant brain tumors

Novel combined immunotherapy promising for treatment of malignant brain tumors

Neural stem cell transplantation promising for Batten disease

Neural stem cell transplantation promising for Batten disease

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Extended hepatitis C treatment increases sustained virological response after liver transplant

Extended hepatitis C treatment increases sustained virological response after liver transplant

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

International Day for Fighting Infection focuses on hospital infection control

International Day for Fighting Infection focuses on hospital infection control

ISHLT announces new guidelines for heart transplant recipients

ISHLT announces new guidelines for heart transplant recipients

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

StemCells to initiate second clinical trial of HuCNS-SC human neural stem cells in NCL

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

SCYNEXIS' SCY-635 inhibitor abstracts accepted for presentation at EASL Annual Meeting

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.